-$0.23 EPS Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter

Equities research analysts expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report ($0.23) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for BioDelivery Sciences International’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.31). BioDelivery Sciences International reported earnings per share of ($0.29) during the same quarter last year, which would indicate a positive year over year growth rate of 20.7%. The company is expected to issue its next earnings report on Friday, March 16th.

On average, analysts expect that BioDelivery Sciences International will report full year earnings of $0.16 per share for the current year, with EPS estimates ranging from $0.08 to $0.28. For the next financial year, analysts expect that the business will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.93) to ($0.41). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. The company had revenue of $11.25 million for the quarter, compared to analysts’ expectations of $9.40 million. During the same period last year, the firm earned ($0.30) earnings per share. BioDelivery Sciences International’s quarterly revenue was up 215.1% on a year-over-year basis.

A number of analysts have weighed in on BDSI shares. Piper Jaffray Companies set a $4.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Sunday, October 22nd. HC Wainwright began coverage on BioDelivery Sciences International in a research report on Sunday, September 10th. They set a “buy” rating and a $5.00 target price on the stock. Roth Capital set a $5.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Monday, November 13th. Cantor Fitzgerald set a $5.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Thursday, October 12th. Finally, ValuEngine cut BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $4.29.

In related news, CEO Mark A. Sirgo sold 24,516 shares of the firm’s stock in a transaction dated Tuesday, September 19th. The stock was sold at an average price of $2.75, for a total transaction of $67,419.00. Following the transaction, the chief executive officer now owns 1,509,262 shares of the company’s stock, valued at $4,150,470.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Mark A. Sirgo sold 50,000 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $2.95, for a total value of $147,500.00. Following the transaction, the chief executive officer now directly owns 1,509,262 shares in the company, valued at approximately $4,452,322.90. The disclosure for this sale can be found here. Insiders have sold 402,127 shares of company stock worth $1,142,798 in the last quarter. Insiders own 9.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its holdings in shares of BioDelivery Sciences International by 138.2% during the third quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 20,599 shares during the last quarter. Valley National Advisers Inc. grew its holdings in shares of BioDelivery Sciences International by 59.0% during the second quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock worth $106,000 after buying an additional 14,000 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of BioDelivery Sciences International during the third quarter worth about $116,000. Cutter & CO Brokerage Inc. grew its holdings in shares of BioDelivery Sciences International by 2.4% during the second quarter. Cutter & CO Brokerage Inc. now owns 43,430 shares of the specialty pharmaceutical company’s stock worth $122,000 after buying an additional 1,000 shares during the last quarter. Finally, Advisor Group Inc. grew its holdings in shares of BioDelivery Sciences International by 42.1% during the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 13,341 shares during the last quarter. 44.18% of the stock is currently owned by hedge funds and other institutional investors.

BioDelivery Sciences International (NASDAQ:BDSI) traded up $0.03 during trading on Monday, reaching $2.75. The company’s stock had a trading volume of 475,367 shares, compared to its average volume of 539,808. BioDelivery Sciences International has a one year low of $1.55 and a one year high of $3.60. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.07 and a current ratio of 1.28.

TRADEMARK VIOLATION NOTICE: This news story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.thelincolnianonline.com/2017/12/07/0-23-eps-expected-for-biodelivery-sciences-international-inc-bdsi-this-quarter.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply